AI assistant
ANGIODYNAMICS INC — Director's Dealing 2019
Feb 1, 2019
32939_dirs_2019-02-01_35fcb19f-8ffe-475f-9d3c-63f91bcf2652.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2019-01-23
Reporting Person: Boucher Brent J. (SVP and GM of Oncology)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 14033 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy) | $16.38 | 2028-01-17 | Common Stock (25000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $16.13 | 2028-02-12 | Common Stock (25000) | Direct | |
| Non-Qualified Stock Option (right to buy) | $20.93 | 2028-07-18 | Common Stock (14412) | Direct | |
| Performance Right | $0 | Common Stock (9048) | Direct |
Footnotes
F1: This number includes (i) 3,750 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") underlying restricted stock units, of which 1,250 shares will vest on each of January 17, 2020, 2021 and 2022, (ii) 5,000 shares of Common Stock of the Company underlying restricted stock units, of which 1,250 shares will vest on each of February 12, 2019, 2020, 2021 and 2022 and (iii) 4,524 shares of Common Stock of the Company underlying restricted stock units, of which 1,131 shares will vest on each of July 18, 2019, 2020, 2021 and 2022.
F2: These stock options vest in four annual installments beginning on January 17, 2019, such that 6,250 options vested on January 17, 2019 and 6,250 options will vest on each of January 17, 2020, 2021 and 2022.
F3: These stock options vest in four annual installments beginning on February 12, 2019, such that 6,250 options will vest on each of February 12, 2019, 2020, 2021 and 2022.
F4: These stock options vest in four annual installments beginning on July 18, 2019, such that 3,603 options will vest on each of July 18, 2019, 2020, 2021 and 2022.
F5: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in column 3 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.